Rating Change
Canaccord Genuity analysts reiterated a Buy rating on TransMedics Group, Inc. (NASDAQ:TMDX) on June 30, 2026.
reiterateNASDAQ:TMDX
Canaccord Genuity Reiterates Buy Rating on TransMedics Group, Inc. (TMDX)
Rating Change Canaccord Genuity analysts reiterated a Buy rating on TransMedics Group, Inc. (NASDAQ:TMDX) on June 30, 2026. Market Context TransMedics Group, Inc.
Market Context
TransMedics Group, Inc. operates in the Healthcare sector. The stock currently trades at $66.42 with a market capitalization of $4.4B.
Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for TransMedics Group, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for TransMedics Group, Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 30, 2026 | Canaccord Genuity | Buy | N/A |
| Jun 18, 2026 | Stifel | Hold | N/A |
| May 26, 2026 | Stifel | Hold | N/A |
| May 06, 2026 | Canaccord Genuity | Buy | N/A |
| May 06, 2026 | Piper Sandler | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View TMDX Stock Page
Frequently Asked Questions
What does a Buy rating mean for TMDX?
A Buy rating from Canaccord Genuity reflects the analyst's outlook on TransMedics Group, Inc. (NASDAQ:TMDX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TMDX forecast page.